Valuation: Natera, Inc.

Market Cap 62.85B 56.29B 51.93B 47B 87.88B 5,985B 89.3B 620B 247B 3,132B 236B 231B 9,920B P/E 2026 *
-304x
P/E 2027 * -3,887x
Enterprise Value 61.76B 55.32B 51.03B 46.18B 86.36B 5,881B 87.75B 609B 243B 3,078B 232B 227B 9,748B EV / Sales 2026 *
21.2x
EV / Sales 2027 * 17.5x
Free-Float
97.24%
Yield 2026 *
-
Yield 2027 * -
1 day+2.73%
1 week+8.63%
Current month+5.49%
1 month+5.18%
3 months+71.78%
6 months+123.88%
Current year+90.32%
1 week 400
Extreme 400
436.19
1 month 380.39
Extreme 380.39
437.41
Current year 181
Extreme 181
437.41
1 year 181
Extreme 181
437.41
3 years 37.66
Extreme 37.665
437.41
5 years 26.1
Extreme 26.1
437.41
10 years 7.35
Extreme 7.35
437.41
Manager TitleAgeSince
Chief Executive Officer 47 02/01/2019
President 46 01/09/2023
Director of Finance/CFO 45 01/02/2017
Director TitleAgeSince
Chairman 53 01/05/2015
Director/Board Member 53 01/01/2007
Director/Board Member 47 02/01/2019
Date Insider Type Main position Quantity % Market Cap. Importance
10/15/26 A Exercice

Founder

150,000 0.1041%
10/7/26 A Don

Founder

-6,000 0.0042%
10/1/26 A Sell

Chief Executive Officer

-1,273 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
+2.73%+8.63%+126.13%+1,039.57% 62.85B
+0.42%-4.39%+12.07%+36.26% 116B
+3.21%+2.30%+2.07%+112.21% 104B
+2.20%+11.59%+48.37%+85.04% 29.89B
+1.35%+3.74%-7.04%+92.23% 29.55B
+2.97%+3.96%+44.71%+98.09% 27.83B
+0.77%-0.02%+29.37%+409.36% 21.79B
-0.72%+5.53%-18.98%-7.55% 20.66B
0.00%-0.63%-4.27%+31.71% 17.09B
-3.98%-26.53%-24.43%+46.05% 13.03B
Average +0.89%+0.13%+20.80%+194.30% 44.17B
Weighted average by Cap. +1.56%+1.19%+26.88%+224.21%

Financials

2026 *2027 *
Net sales 2.91B 2.61B 2.4B 2.18B 4.07B 277B 4.14B 28.69B 11.45B 145B 10.92B 10.69B 459B 3.52B 3.15B 2.91B 2.63B 4.92B 335B 5B 34.68B 13.84B 175B 13.2B 12.92B 555B
Net income -203M -182M -168M -152M -284M -19.36B -289M -2B -799M -10.13B -763M -747M -32.08B -8.5M -7.61M -7.03M -6.36M -11.89M -810M -12.08M -83.81M -33.44M -424M -31.91M -31.23M -1.34B
Net Debt -1.09B -975M -900M -814M -1.52B -104B -1.55B -10.73B -4.28B -54.25B -4.09B -4B -172B -1.4B -1.26B -1.16B -1.05B -1.96B -134B -2B -13.84B -5.52B -69.97B -5.27B -5.16B -222B
Projected Income Statement - Annual - Natera, Inc.
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
29/10/26 $436.00 +2.73% 1,326,459
28/10/26 $424.42 +3.31% 1,548,874
27/10/26 $410.82 +1.46% 1,713,547
26/10/26 $404.90 +0.24% 1,429,671
23/10/26 $403.95 +0.64% 1,102,134
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
MarketScreener Ratings - Natera, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
436.00USD
Average target price
416.39USD
Spread / Average Target
-4.50%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Natera, Inc.
  1. Stock Market
  2. Stocks
  3. NTRA Stock